Abdalla Mahmoud El-Mowafy

Abdalla Mahmoud El-Mowafy

Auto-generated profile, based on publicly available information

Abdalla Mahmoud El-Mowafy

Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 May 2003 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
AEAbdalla M. El-Mowafy
Abdalla M. El-Mowafy
MAMoussa Alkhalaf
Moussa Alkhalaf
Resveratrol (RSVL) is a well-established chemopreventive agent in human breast cancer models. The molecular basis of its action is far less characterized. We investigated the effects of RSVL on activity of adenylate- and guanylate-cyclase (AC, GC) enzymes; two known cytostatic cascades in MCF-7 breast cancer cells. RSVL increased cAMP levels in both time- and concentration-dependent manners ( t1/2 , 6.2 min; EC 50 0.8 µM). In contrast, it had no effect on cGMP levels. The stimulatory effects for RSVL on AC were not altered either by the protein synthesis inhibitor (actinomycin-D, 5 µM) or the estrogen-receptor (ER) blockers (tamoxifen and ICI182,780, 1 µM each). Likewise, cAMP formation by RSVL was insensitive to either the broad-spectrum phosphodiesterase (PDE) inhibitor (IBMX, 0.5 mM) or the cAMP-specific PDE inhibitor (rolipram, 10 µM). Instead, these PDE inhibitors significantly augmented maximal cAMP formation by RSVL. Parallel experiments showed that either RSVL or rolipram inhibited the proliferation of these cells in a concentration-responsive manner. Further, concurrent treatment with RSVL and rolipram significantly enhanced their individual cytotoxic responses. The antiproliferative effects were appreciably reversed by the kinase-A inhibitors, Rp-cAMPS (100–300 µM) or KT-5720 (10 µM). Pretreatment with the cPLA 2 inhibitor arachidonyl trifluoromethyl ketone (10 µM) markedly antagonized the cytotoxic effects of RSVL, but had no effect on that of rolipram. Altogether, the present study demonstrates, for the first time, that the chemotherapeutic agent RSVL is an agonist for the cAMP/kinase-A system, a documented pro-apoptic and cell-cycle suppressor in breast cancer cells.


1 December 2010 in Phytomedicine
Verified
Journal Article
Closed access
AEA.M. El-Mowafy
A.M. El-Mowafy
MAMohammed Al-Gayyar
Mohammed Al-Gayyar
HSH.A. Salem
H.A. Salem
MEM.E. El-Mesery
M.E. El-Mesery
MDM.M. Darweish
M.M. Darweish

15 April 2014 in Drugs in R&D
Verified
Journal Article
Open access
PDF file
MAMarwa A. Abdel-Dayem
Marwa A. Abdel-Dayem
AEAhmed A. Elmarakby
Ahmed A. Elmarakby
AAAzza A. Abdel-Aziz
Azza A. Abdel-Aziz
CPChelsey Pye
Chelsey Pye
SSShehta A. Said
Shehta A. Said
AEAbdalla M. El-Mowafy
Abdalla M. El-Mowafy
Background The polyunsaturated, ω-3 fatty acid, docosahexaenoic acid (DHA), claims diverse cytoprotective potentials, although via largely undefined triggers. Thus, we currently first tested the ability of DHA to ameliorate valproate (VPA)-evoked hepatotoxicity, to modulate its anticonvulsant effects, then sought the cellular and molecular basis of such actions. Lastly, we also verified whether DHA may kinetically alter plasma levels/clearance rate of VPA. Methods and Results VPA (500 mg/kg orally for 14 days in rats) evoked prominent hepatotoxicity that appeared as a marked rise (2- to 4-fold) in serum hepatic enzymes (γ-glutamyl transferase [γ-GT], alanine aminotransferase [ALT], and alkaline phosphatase [ALP]), increased hepatic lipid peroxide (LPO) and tumor necrosis factor-alpha (TNFα) levels, as well as myeloperoxidase (MPO) activity (3- to 5-fold), lowering of serum albumin (40 %), and depletion of liver reduced-glutathione (GSH, 35 %). Likewise, histopathologic examination revealed hepatocellular degeneration, replacement by inflammatory cells, focal pericentral necrosis, and micro/macrovesicular steatosis. Concurrent treatment with DHA (250 mg/kg) markedly blunted the elevated levels of liver enzymes, lipid peroxides, TNFα, and MPO activity, while raising serum albumin and hepatic GSH levels. DHA also alleviated most of the cytologic insults linked to VPA. Besides, in a pentylenetetrazole (PTZ) mouse convulsion model, DHA (250 mg/kg) markedly increased the latency in convulsion evoked by VPA, beyond their individual responses. Lastly, pharmacokinetic studies revealed that joint DHA administration did not alter serum VPA concentrations. Conclusions DHA substantially ameliorated liver injury induced by VPA, while also markedly boosted its pharmacologic effects. DHA manipulated definite cellular machinery to curb liver oxidative stress and inflammation, without affecting VPA plasma levels. Collectively, these protective and synergy profiles for DHA propose a superior VPA-drug combination regimen.

1 February 2008 in Archives of Medical Research
Verified
Journal Article
Closed access
MAMoussa Alkhalaf
Moussa Alkhalaf
AEAbdulla El-Mowafy
Abdulla El-Mowafy
WRWaleed M. Renno
Waleed M. Renno
OROusama Rachid
Ousama Rachid
AAAhmed Ali
Ahmed Ali
RARajaa Al-Attyiah
Rajaa Al-Attyiah